UK industry challenges generalisation of studies slamming monitoring
This article was originally published in Clinica
Researchers questioning the clinical value and cost-effectiveness of blood glucose self-monitoring in type 2 (non-insulin-dependent) diabetes have rekindled a decade-long debate on the issue. The main findings of two studies published today by the British Medical Journal (BMJ) are that routine testing may be wasting around £100m ($198m) a year, with little glycaemic control benefit and, reputedly, worse quality of life.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.